🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

624 results for “Solid” Clear

  1. CEP-9722

    Teva Pharma GmbH

    Solid Tumors

    phase 2 small molecule terminated

    1 trial

  2. CISPLATIN, CARBOPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CISPLATIN, FLUOROURACIL

    Takeda Pharmaceuticals International AG

    Solid Neoplasm

    phase 2 small molecule active

    1 trial

  3. CM-24 and Nivolumab - Dose Escalation

    PURPLE BIOTECH LTD.

    Solid Tumor

    phase 2 small molecule completed

    1 trial

  4. CR-001

    CRESCENT BIOPHARMA, INC.

    Locally Advanced / Metastatic Solid Tumors

    phase 2 small molecule active

    1 trial

  5. CRB-601 monoclonal antibody

    Corbus Pharmaceuticals Holdings

    Solid Tumor

    phase 2 small molecule active

    1 trial

  6. CRB-701

    Corbus Pharmaceuticals Holdings

    Solid Tumor, Adult

    phase 2 small molecule active

    1 trial

  7. CTX-009 (ABL001)

    Compass Therapeutics

    P1b: Advanced Solid Tumors

    phase 2 small molecule terminated

    1 trial

  8. CX-072

    CytomX Therapeutics

    Solid Tumor

    phase 2 small molecule terminated

    2 trials

  9. CX-2009

    CytomX Therapeutics

    Solid Tumor, Adult

    phase 2 small molecule terminated

    1 trial

  10. CX-2029

    CytomX Therapeutics

    Solid Tumor, Adult

    phase 2 small molecule completed

    1 trial

  11. Campto 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Campto 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, DEXAMETHASONE , Temodal 180 mg hard capsules, Temodal 5 mg hard capsules, Temodal 140 mg hard capsules, Temodal 100 mg hard capsules, Campto 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Temodal 20 mg hard capsules, Temodal 250 mg hard capsules

    Inhibrx Biosciences

    Advanced or metastatic solid tumors

    phase 2 small molecule active

    1 trial

  12. Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Paclitaxel Bendalis 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Mycofit, 250 mg, kapsułki twarde, Remsima 100 mg powder for concentrate for solution for infusion, volrustomig, Cyramza 10 mg/ml concentrate for solution for infusion

    AstraZeneca AB

    Solid Tumors, SQ, NSQ NSCLC

    phase 2 small molecule active

    1 trial

  13. Cemiplimab

    Regeneron UK Limited

    Metastatic Solid Tumor

    phase 2 small molecule active

    1 trial

  14. Cetuximab

    Solid Biosciences

    Head and Neck Neoplasm

    phase 2 small molecule completed

    1 trial

  15. DCC-3084, DCC-3084

    Pharma Mar S.A.

    Solid tumors driven by the MAPK Pathway

    phase 2 small molecule active

    1 trial

  16. DS-3939a

    Daiichi Sankyo Europe GmbH

    Metastatic Solid Tumor, Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  17. DS-8201a

    AstraZeneca AB

    Treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology

    phase 2 small molecule active

    1 trial

  18. DZR123, DZR123, ENZALUTAMIDE

    Novartis Ophthalmics Europe

    advanced, solid, relapsed tumors / advanced tumors: human lymphomas / solid human tumor indications (urothelial carcinoma, or other advanced/metastatic solid tumors, ovarian clear cell cancer, endometrial carcinoma, lymphoma including peripheral T-cell Lymphoma and GCBDLBCL, malignant pleural or peritoneal mesothelioma, metastatic castration - resistant prostate cancer (mCRPC))

    phase 2 small molecule active

    1 trial

  19. Daraxonrasib

    Revolution Medicines

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  20. Dazostinag

    Takeda Pharmaceuticals International AG

    Solid Neoplasms

    phase 2 small molecule completed

    1 trial

  21. Decoy20

    BRIGHT MINDS BIOSCIENCES INC.

    Solid Tumor, Adult

    phase 2 small molecule active

    1 trial

  22. E7386, Doxorubicin EBEWE 2 mg/ml koncentratas infuziniam tirpalui, E7386, Паклитаксел Ебеве 6 mg/ml концентрат за инфузионен разтвор, Paclitaxel Aurobindo 6 mg/ml concentrato per soluzione per infusione, Doxorubicina Aurobindo 2 mg/ml concentrato per soluzione per infusione, LENVIMA 10 mg hard capsules, LENVIMA 4 mg hard capsules

    Eisai GmbH

    Hepatocellular carcinoma, colorectal cancer, endometrial cancer, or other solid tumor

    phase 2 small molecule active

    1 trial

  23. EIK1003 5mg Tablets, PREDNISONE , ABIRATERONE , EIK1003 20mg Tablets, PACLITAXEL

    Eikon Therapeutics

    Advance solid tumors

    phase 2 small molecule active

    1 trial

  24. EIK1004 20mg Tablets, EIK1004 5mg Tablets

    Eikon Therapeutics

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources